2.158SEK-1.01%Mkt Cap: 536.50M SEKP/E: 3.37Last update: 2026-06-01
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind I…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap536.50M SEK
Enterprise Value283.94M SEK
Revenue (TTM)317.21M SEK
Gross Profit317.21M SEK
Net Income (TTM)146.97M SEK
Revenue/Share1.276 SEK
Last Price2.158 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees22
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)3.37
P/E (Forward)-2.32
PEG—
EV/EBITDA1.72
EV/Revenue0.90
P/S1.71
P/B2.32
EPS (TTM)0.64
EPS (Forward)-0.94
52W Range
1.00021% of range6.590
52W High6.590 SEK
52W Low1.000 SEK
Profitability
Gross Margin100.00%
Oper. Margin-7261.81%
EBITDA Margin52.09%
Profit Margin46.41%
ROE55.28%
ROA49.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF150.13M SEK
CapEx (TTM)472.00K SEK
FCF Margin28.39%
FCF Yield16.79%
Net Debt-258.03M SEK
Net Debt/EBITDA-1.56
Balance Sheet
Debt/Equity—
Current Ratio8.09
Quick Ratio7.99
Book Value/Sh0.9410 SEK
Cash/Share1.038 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)10.00 SEK
Target Range6.000 SEK – 14.00 SEK
# Analysts2
Ownership
Shares Out.248.61M
Float236.26M
Insiders16.96%
Institutions27.24%
Technical
SMA 503.712 (-41.9%)
SMA 2003.785 (-43.0%)
Beta1.65
S&P 52W Chg27.70%
Avg Vol (30d)1.93M
Avg Vol (10d)3.09M
Technical Indicators
RSI (14)17.6
MACD-0.3124
MACD Signal-0.2322
MACD Hist.-0.0802
BB Upper4.068 SEK
BB Middle3.298 SEK
BB Lower2.527 SEK
BB Width46.74%
ATR (14)0.2610 SEK
Vol Ratio (20d)7.55x